In a new study presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois, BERG showed preliminary data that a drug using artificial intelligence could slow the growth of cancer in clinical trials.
The interim data from ongoing Phase I of BPM 31510 (IV) in advanced solid tumors demonstrated the potential of metabolically-driven therapy by reversing the Warburg effect, the phenomenon when cancer cells change their energy supply. It appears to change the metabolism of the cancer cells making the cancer microenvironment ready to induce cell death.
The data from 85 patients showed signs the approach could kill tumors. The trial was designed to test only for toxicity, but in one patient the tumor shrank by a 25 percent.
BPM 31510 (IV) is one of the first cancer drugs developed through the guidance of artificial intelligence. The drug will now be taken into more advanced trials.
"It remains to be seen if a drug developed using this information will help cancer patients, but we need to keep finding new ways to find innovative treatments for patients," said Dr. Alan Worsley, from Cancer Research UK.